Sugi Predict

Sugi Predict / Targets / CHRNA4

CHRNA4

Neuronal acetylcholine receptor subunit alpha-4 · P43681 · CHRNA4 on Sugi Atlas →

201,836 patent compounds predicted against CHRNA4, 97,685 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Radafaxine Radafaxine (SCHEMBL48964) 1.00 20/20
SCHEMBL80066 SCHEMBL80066 0.65 12/20
Bromide Bromide (SCHEMBL69311) 0.62 11/20
Dl-Anabasine Dl-Anabasine (SCHEMBL117530) 1.00 10/20
SCHEMBL80814 SCHEMBL80814 0.72 10/20
SCHEMBL5335 SCHEMBL5335 0.87 8/20
SCHEMBL100931 SCHEMBL100931 0.60 8/20
SCHEMBL80826 SCHEMBL80826 0.58 8/20
SCHEMBL81218 SCHEMBL81218 0.53 8/20
SCHEMBL81293 SCHEMBL81293 0.51 8/20
SCHEMBL105590 SCHEMBL105590 0.51 8/20
SCHEMBL52844 SCHEMBL52844 0.69 7/20
SCHEMBL5109 SCHEMBL5109 0.61 7/20
SCHEMBL118352 SCHEMBL118352 0.57 7/20
SCHEMBL57209 SCHEMBL57209 0.60 6/20
SCHEMBL133904 SCHEMBL133904 0.58 6/20
SCHEMBL82301 SCHEMBL82301 0.54 6/20
SCHEMBL20436 SCHEMBL20436 0.46 6/20
SCHEMBL8314 SCHEMBL8314 1.00 5/20
Bupropion Bupropion (SCHEMBL38777) 1.00 5/20

Clinical trials — most relevant to CHRNA4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Postoperative Sugammadex After COVID-19 PHASE4UNKNOWN
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail PHASE1/PHASE2COMPLETED
Nicotinic Receptor Augmentation of SSRI Antidepressants PHASE2COMPLETED
A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence PHASE2COMPLETED
Varenicline (Chantix™) for the Treatment of Alcohol Dependence PHASE2COMPLETED
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism PHASE1/PHASE2COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition PHASE2RECRUITING
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
Gene Therapy for Alzheimer's Disease Clinical Trial PHASE1COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine PHASE1WITHDRAWN
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Brain Imaging in Alzheimer's Disease nanCOMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia nanCOMPLETED
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia nanCOMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNA4 binder may also engage these)

ProteinNameSimilarity
Q5IS77 — 1.000 Q5IS77 →
P09483 — 1.000 P09483 →
O70174 — 1.000 O70174 →
Q19AE6 — 0.999 Q19AE6 →
P09482 — 0.991 P09482 →
P09480 — 0.990 P09480 →
GABRQ Gamma-aminobutyric acid receptor subunit thet 0.987 landscape →
Q5IS51 — 0.987 Q5IS51 →
Q9JLF1 — 0.985 Q9JLF1 →
P09484 — 0.984 P09484 →
CHRNA2 Neuronal acetylcholine receptor subunit alpha 0.984 landscape →
Q8R4G9 — 0.984 Q8R4G9 →
Q07263 — 0.983 Q07263 →
Q5IS52 — 0.983 Q5IS52 →
CHRNA5 Neuronal acetylcholine receptor subunit alpha 0.983 landscape →
Q91X60 — 0.983 Q91X60 →
CHRNA6 Neuronal acetylcholine receptor subunit alpha 0.982 landscape →
P49581 — 0.981 P49581 →
P17644 — 0.981 P17644 →
Q8R493 — 0.980 Q8R493 →
P18257 — 0.980 P18257 →
Q27218 — 0.979 Q27218 →
P12389 — 0.978 P12389 →
B2RXE2 — 0.978 B2RXE2 →
P13908 — 0.978 P13908 →
A8XNX8 — 0.978 A8XNX8 →
P43143 — 0.977 P43143 →
CHRNA3 Neuronal acetylcholine receptor subunit alpha-3 0.977 landscape →
Q9TUI4 — 0.977 Q9TUI4 →
CHRNB4 Neuronal acetylcholine receptor subunit beta- 0.977 landscape →